Edgewise Therapeutics Bundle
What is Edgewise Therapeutics's Journey?
Edgewise Therapeutics, founded in 2017, is a clinical-stage biopharmaceutical company focused on severe inherited muscle disorders and cardiac conditions. Headquartered in Boulder, Colorado, its mission is to develop first-in-class medicines targeting muscle modulators.
The company has made significant strides, advancing drug candidates like sevasemten for muscular dystrophies and EDG-7500 for hypertrophic cardiomyopathy. Positive Phase 2 trial results were reported in late 2024 and early to mid-2025, bolstering its development pipeline.
Edgewise Therapeutics has a strong financial footing, with approximately $594 million in cash as of June 30, 2025. Its market capitalization hovers around $1.45 billion to $1.47 billion as of August 2025. The company is dedicated to creating orally bioavailable, small molecule therapies to improve patient lives. Learn more about its market position in our Edgewise Therapeutics PESTEL Analysis.
What is the Edgewise Therapeutics Founding Story?
The Edgewise Therapeutics history began in 2017, with official incorporation dates in May and December of that year. Established in Boulder, Colorado, the company was founded by a team of experienced professionals with a shared vision for addressing severe musculoskeletal diseases.
Founding Story of Edgewise Therapeutics
Edgewise Therapeutics was founded in 2017 by Badreddin Edris, Peter Thompson, and Alan Russell, bringing together significant expertise from previous ventures in the biotech sector. Their primary goal was to develop novel treatments for debilitating muscle conditions.
- Founded in 2017 in Boulder, Colorado.
- Founders include Badreddin Edris, Peter Thompson, and Alan Russell.
- Focused on treating high morbidity musculoskeletal diseases.
- Initial product candidate was EDG-001, later known as sevasemten (EDG-5506).
- Targeted conditions like Duchenne and Becker muscular dystrophies.
The founders identified a critical unmet need in treating muscle damage caused by contraction, particularly in conditions like Duchenne and Becker muscular dystrophies. Their initial strategy involved creating first-in-class medicines that would directly impact muscle components to prevent such damage. This led to the development of EDG-001, which eventually evolved into sevasemten (EDG-5506), their lead therapeutic candidate.
Securing substantial early-stage funding was crucial for the Edgewise Therapeutics company evolution. The company successfully raised a total of $145 million across two significant funding rounds. A Series B round in September 2019 brought in $50 million, followed by a substantial Series C round of $95 million in December 2020. Key investors in these rounds included USVP, Novo Holdings, and Viking Global Investors. The support from CureDuchenne Ventures also highlighted the importance of patient advocacy in the company's early development. This foundational capital was instrumental in navigating the complexities of biopharmaceutical startup development and advancing their pipeline into preclinical and early clinical stages, a key milestone in the Competitors Landscape of Edgewise Therapeutics.
Edgewise Therapeutics SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
What Drove the Early Growth of Edgewise Therapeutics?
Founded in 2017, Edgewise Therapeutics rapidly advanced its pipeline, focusing on sevasemten for muscular dystrophies and EDG-7500 for hypertrophic cardiomyopathy. The company's early years were marked by significant progress in clinical development and strategic financial growth.
Advancing Lead Product Candidates
Edgewise Therapeutics concentrated on sevasemten (EDG-5506) for Duchenne and Becker muscular dystrophies and EDG-7500 for hypertrophic cardiomyopathy. This focus guided its initial development strategy.
Transition to Clinical Trials
The company initiated its Phase 1 trial for EDG-5506 in 2020, first in healthy volunteers and then in adults with Becker muscular dystrophy. This marked a crucial step from preclinical research to human testing.
Expanding Clinical Studies
Multiple Phase 2 trials for sevasemten, including ARCH, CANYON, GRAND CANYON, DUNE, MESA, LYNX, and FOX, were launched to assess its safety and efficacy. EDG-7500 also entered Phase 2 development with the CIRRUS-HCM trial.
Team and Infrastructure Growth
The workforce grew significantly, from 33 employees in December 2022 to 126 by June 2025. A state-of-the-art muscle research facility was established in Boulder, Colorado, supporting this expansion.
Financial Milestones and Market Confidence
Following a successful IPO in March 2021 that raised $202.4 million, the company secured additional funding through a public follow-on offering in early 2024 for approximately $232 million and another in April 2025 for $188 million. Analysts generally maintain a 'Moderate Buy' rating, indicating confidence in the company's progress and its Target Market of Edgewise Therapeutics.
Edgewise Therapeutics PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
What are the key Milestones in Edgewise Therapeutics history?
Edgewise Therapeutics has navigated the complex biopharmaceutical landscape by achieving significant milestones and introducing key innovations, all while managing inherent developmental challenges. The company's journey, detailed in the Brief History of Edgewise Therapeutics, highlights its focus on novel therapies for rare muscle diseases.
| Year | Milestone |
|---|---|
| 2023 | Received Fast Track and Orphan Drug Designations from the FDA and EMA for sevasemten (EDG-5506) for Duchenne and Becker muscular dystrophies, along with Rare Pediatric Disease Designation for Duchenne. |
| 2024 | Reported positive two-year topline results from the ARCH open-label trial of sevasemten in adults with Becker muscular dystrophy, showing sustained disease stabilization. Completed a $232 million public offering. |
| 2024 | Announced positive topline data from the Phase 2 CANYON placebo-controlled trial in Becker patients. |
| 2025 | Completed enrollment in the GRAND CANYON pivotal global cohort for Becker muscular dystrophy. Reported positive initial results for EDG-7500 in obstructive hypertrophic cardiomyopathy. Secured $188 million in funding. |
The company's core innovation is sevasemten (EDG-5506), an orally administered, first-in-class fast skeletal myosin inhibitor designed to protect muscle from damage. Another significant innovation is EDG-7500, a novel cardiac sarcomere modulator currently in Phase 2 development for hypertrophic cardiomyopathy and other diastolic dysfunction disorders.
Fast Skeletal Myosin Inhibition
Edgewise Therapeutics developed sevasemten (EDG-5506), a first-in-class oral therapy targeting fast skeletal myosin. This mechanism aims to protect muscle tissue from damage caused by contractions.
Cardiac Sarcomere Modulation
The company is advancing EDG-7500, a novel cardiac sarcomere modulator. This therapy is being investigated for its potential to treat conditions like hypertrophic cardiomyopathy.
Regulatory Designations
Edgewise Therapeutics has secured important regulatory designations, including Fast Track and Orphan Drug status for sevasemten. These designations are crucial for accelerating the development and review process for rare diseases.
The company faces challenges typical of early-stage biotechs, including reliance on the success of its lead drug candidates, sevasemten and EDG-7500, as clinical trial outcomes are critical for future growth. Maintaining adequate funding is also a constant consideration, especially for advancing costly late-stage trials, although recent capital raises in 2024 and 2025 totaling over $400 million provide a strong financial footing.
Clinical Trial Risks
The success of Edgewise Therapeutics is heavily dependent on the outcomes of its clinical trials for sevasemten and EDG-7500. These trials carry inherent risks associated with drug development, including efficacy and safety findings.
Patient Recruitment
Recruiting and retaining patients for rare disease clinical trials presents ongoing challenges. This can impact the timeline and feasibility of studies, requiring strategic patient engagement efforts.
Potential Safety Signals
Earlier data for EDG-7500 indicated a potential atrial fibrillation signal in a subset of patients. Careful monitoring and management of such signals are critical in ongoing and future clinical development.
Edgewise Therapeutics Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What is the Timeline of Key Events for Edgewise Therapeutics?
The Edgewise Therapeutics company overview reveals a dynamic journey from its founding in 2017 to its current position as a significant player in developing therapies for muscle and cardiac disorders. This Edgewise Therapeutics history is marked by strategic funding, clinical trial advancements, and key regulatory milestones, illustrating the company's focused development path.
| Year | Key Event |
|---|---|
| 2017 | Edgewise Therapeutics was founded in Boulder, Colorado, marking the beginning of its corporate history. |
| Sep 17, 2019 | The company completed a Series B funding round, successfully raising $50 million to fuel its development efforts. |
| 2020 | Edgewise Therapeutics initiated a Phase 1 clinical trial for EDG-5506, a significant step in its drug development pipeline. |
| Dec 8, 2020 | A Series C funding round was completed, bringing in $95 million to further advance its research and clinical programs. |
| March 2021 | The company achieved a major milestone with its Initial Public Offering (IPO), raising $202.4 million. |
| Nov 30, 2023 | EDG-5506 received Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA, highlighting its potential for rare diseases. |
| April 2024 | Positive two-year topline results from the ARCH open-label trial of sevasemten in Becker muscular dystrophy were reported. |
| Dec 2024 | The company announced positive topline results from the Phase 2 CANYON trial of sevasemten in Becker muscular dystrophy. |
| Jan 2025 | Edgewise Therapeutics announced its 2025 priorities at the J.P. Morgan Healthcare Conference and completed a $232 million public follow-on offering. |
| Feb 2025 | Enrollment was completed in the GRAND CANYON pivotal placebo-controlled cohort for Becker muscular dystrophy. |
| Q1 2025 | Initial 28-day data from the Phase 2 CIRRUS-HCM trial for EDG-7500 in hypertrophic cardiomyopathy were reported. |
| April 2025 | An additional public offering was completed, raising approximately $188 million. |
| Q2 2025 | Data from Phase 2 LYNX and FOX trials in Duchenne muscular dystrophy were reported, alongside a narrower Q2 2025 net loss of $0.34 per share. |
| June 26, 2025 | Positive results in the sevasemten program for both Becker and Duchenne muscular dystrophies were unveiled. |
Muscular Dystrophy Program Advancements
Edgewise Therapeutics is progressing its sevasemten program for Becker muscular dystrophy, aiming for end-of-Phase 2 feedback from the FDA in the first half of 2025. The company anticipates topline data from the GRAND CANYON trial in the fourth quarter of 2026.
Duchenne Muscular Dystrophy Strategy
For Duchenne muscular dystrophy, Edgewise plans to discuss Phase 3 trial design with the FDA in the fourth quarter of 2025, with a pivotal study expected to commence in 2026. This strategic planning is a key part of the Marketing Strategy of Edgewise Therapeutics.
Cardiovascular Pipeline Development
In the cardiovascular arena, 12-week data from the CIRRUS-HCM trial for EDG-7500 in HCM is expected in the second half of 2025. Dosing for the novel heart failure candidate EDG-15400 is slated to begin in the third quarter of 2025.
Future Candidate Identification
The company is also focused on filing an IND application for a second-generation heart failure candidate and selecting a proprietary cardiometabolic drug candidate from preclinical data. This forward-looking approach underscores the company's commitment to innovation.
Edgewise Therapeutics Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Competitive Landscape of Edgewise Therapeutics Company?
- What is Growth Strategy and Future Prospects of Edgewise Therapeutics Company?
- How Does Edgewise Therapeutics Company Work?
- What is Sales and Marketing Strategy of Edgewise Therapeutics Company?
- What are Mission Vision & Core Values of Edgewise Therapeutics Company?
- Who Owns Edgewise Therapeutics Company?
- What is Customer Demographics and Target Market of Edgewise Therapeutics Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.